Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Skin Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Skin Neoplasm

Cancer Family

Skin Neoplasm

CI-CAN-00000051Explore in graph →

Non-malignant346 active trials14 approved drugs74 evidence items

NCIt: C3372
MeSH: D012878

Overview
Statistics
Survival
Genomics19
Variants & evidence74
Drugs32
Trials1424
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (99)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 11, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 76–99 of 99 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
· Clin Cancer Res · 2013 · PMID 24345920 · validated civic_curation pubmed
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
· Pigment Cell Melanoma Res · 2014 · PMID 24495407 · validated civic_curation pubmed
Elucidating distinct roles for NF1 in melanomagenesis.
· Cancer Discov · 2013 · PMID 23171796 · validated civic_curation pubmed
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.
· Oncogene · 2009 · PMID 18794803 · validated civic_curation pubmed
The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.
· Melanoma Res · 2003 · PMID 12777976 · validated civic_curation pubmed
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
· PLoS One · 2011 · PMID 22194965 · validated civic_curation pubmed
Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.
· Oncotarget · 2015 · PMID 26304929 · validated civic_curation pubmed

Showing 76–99 of 99 publications

← Previous
1
2
3
4
Next →

CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.

· Mol Cancer Ther · 2015 · PMID 25852058 · validated civic_curation pubmed

Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma.

· Melanoma Res · 2014 · PMID 24950457 · validated civic_curation pubmed

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

· Cell · 2010 · PMID 20141835 · validated civic_curation pubmed

Bonilla et al. Nat Genet 2016

· 2016 · PMID 26950094 · validated cbioportal_study pubmed

Li et al. Clin Cancer Res 2015

· 2015 · PMID 25589618 · validated cbioportal_study pubmed

Thind, Amarinder Singh et al. Front Oncol 2022

· 2022 · PMID 35982973 · validated cbioportal_study pubmed

Chang et al. NPJ Genom Med 2021

· 2021 · PMID 34272401 · validated cbioportal_study pubmed

Shain et al. Nat Genet 2015

· 2015 · PMID 26343386 · validated cbioportal_study pubmed

Alexander N et al. Clin Cancer Res 2021

· 2021 · PMID 33509808 · validated cbioportal_study pubmed

Hodis et al. Cell 2012

· 2012 · PMID 22817889 · validated cbioportal_study pubmed

Berger et al. Nature 2012

· 2012 · PMID 22622578 · validated cbioportal_study pubmed

Van Allen et al. Science 2015

· 2015 · PMID 26359337 · validated cbioportal_study pubmed

Snyder et al. NEJM 2014

· 2014 · PMID 25409260 · validated cbioportal_study pubmed

TCGA, Cell 2015

· 2015 · PMID 26091043 · validated cbioportal_study pubmed

Catalanotti et al. JCO Precis Oncol 2017

· 2017 · PMID 32913971 · validated cbioportal_study pubmed

Krauthammer et al. Nat Genet 2012

· 2012 · PMID 22842228 · validated cbioportal_study pubmed

Identification of fusions with potential clinical significance in melanoma.

· Mod Pathol · 2022 · PMID 35871080 · validated civic_curation pubmed